Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

A new £1.2 billion science and technology park was formally opened today in Oxford, in a welcome boost to the UK's life sciences sector. The Oxford North campus has consent for around a million square ...

Novartis' third-quarter results have exemplified the reason for its recent deal-making activity, as heart failure therapy Entresto finally succumbed to the entry of ...

MSD and Eisai's combination of Keytruda and Lenvima has become a driver of growth for both products, but their efforts to extend the regimen into liver cancer have hit a hurdle. The two partners said ...

CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a deal that could be worth up to £268 million ($358 million). The object of ...

Roche and partner Klinrisk have picked up a CE-mark in the EU for an AI-based tool that can be used to predict renal function decline in patients with chronic kidney disease (CKD). The algorithm will ...

George Medicines' recently-approved high blood pressure therapy Widaplik could offer a desperately needed new treatment for patients with intracerebral haemorrhage (ICH), the most severe form of ...

AstraZeneca and Daiichi Sankyo pushed back the readout of their trial of Datroway in triple-negative breast cancer (TNBC) patients ineligible for frontline immunotherapies, but the result has been ...

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...

This year's Nobel Prize in Physiology or Medicine has been awarded to three scientists for their work on regulatory T-cells (Tregs), research that has fuelled a well-stocked pipeline of potential new ...

So it was that pharmaphorum sat down with Jan Kirsten, global head of the rare tumour business for SpringWorks Therapeutics – a healthcare company of Merck KGaA – to discuss mirdametinib’s application ...